Autolus Therapeutics To Present Clinical Data Updates At The American Society Of Hematology Annual Meeting 2023 In Two Oral Presentations And Two Poster Presentations
Portfolio Pulse from Benzinga Newsdesk
Autolus Therapeutics plc (NASDAQ:AUTL) will present clinical data updates at the American Society of Hematology Annual Meeting 2023. The presentations will include updates on the ongoing FELIX Phase Ib/II study and MCARTY Phase I Study, as well as data demonstrating the robustness of obe-cel's manufacturing process. The company expects to file a BLA later this year.
November 02, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Autolus Therapeutics is set to present clinical data updates at a major conference, which could potentially influence investor sentiment and the company's stock price.
Presenting clinical data updates at a major conference like the American Society of Hematology Annual Meeting can significantly influence investor sentiment. Positive data can lead to increased investor confidence and potentially drive the stock price up. The company's announcement of an expected BLA filing later this year also adds to the potential positive impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100